Week In Review: Curon Out-Licenses T-Cell-Engager To Merck For $700 Million Upfront

Curon Biopharmaceutical, a Shanghai company, out-licensed global rights for a clinical-stage bispecific candidate to Merck (MSD) for $700 million upfront plus $600 million in milestones.